Plastic surgery clinics are the highest-ticket cosmetic vertical (cases run $5K–$50K+), which makes them attractive for MCA in absolute dollars but riskier on a per-case basis. Revenue is overwhelmingly cash-pay (insurance covers only reconstructive cases like breast reconstruction post-mastectomy or post-trauma). Chargeback risk on dissatisfied cosmetic patients is the dominant underwriting concern.
Typical funding ranges.
- Solo plastic surgeon ($80K–$200K monthly revenue): $100K–$300K advances at 1.25–1.35 factor over 10–14 months.
- Group practice ($200K–$500K monthly revenue): $300K–$750K advances at 1.22–1.32 factor over 12–16 months.
- Multi-location or surgical-center-owning practice ($500K+ monthly revenue): $500K–$1.5M advances at 1.20–1.30 factor over 14–18 months.
What underwriters look for.
First, the case mix. Surgical cases (breast augmentation, rhinoplasty, abdominoplasty, body contouring) drive revenue at $8K–$30K per case. Non-surgical (injectables, lasers) provide steady cash but lower margin. Reconstructive cases (insurance-billed) stabilize cash flow.
Second, the financing-platform exposure. Plastic surgery patients heavily use third-party financing (CareCredit, PatientFi, Cherry, Alphaeon Credit). Funders pull processor statements to confirm these are normal-course AR.
Third, the surgical-facility status. Practices that own an AAAASF or AAAHC-accredited ASC (ambulatory surgery center) have higher revenue per case and better economics.
Fourth, the malpractice posture. Funders pull surgeon CV, board certification (ABPS), and any state-board disciplinary actions. Aesthetic-only surgeons without ABPS certification get worse terms.
Common uses.
- Equipment (lasers, body contouring like CoolSculpting, surgical instruments).
- ASC build-out or expansion.
- Marketing (plastic surgery CAC is $300–$1,000 per new surgical consult).
- Hire associate surgeon or nurse injector.
- Acquisition of competing practice.
What to watch out for.
Chargeback risk is the dominant landmine. A single $25K rhinoplasty chargeback can wipe out a week of MCA collections. Funders typically include clawback clauses allowing them to debit the operating account if chargebacks exceed 1% of monthly revenue.
Financing-platform clawbacks (CareCredit recourse, PatientFi default exposure) can also hit. A practice with $200K/month in CareCredit-financed revenue may face $20K+/month in default-related write-downs.
State considerations.
California, Florida, Texas, New York, and Georgia have the highest plastic surgery MCA activity. Florida has unique medical-tourism dynamics (Miami being a destination market). California enforces strict surgeon licensure and corporate-practice rules.
APR-equivalent reality check.
A 1.28 factor over a 12-month term is roughly 48–55% APR. Compare to plastic-surgery-specialty lenders (Lendeavor, GreenSky for practices), CareCredit business credit, or SBA 7(a). MCA only makes sense for time-sensitive needs.
Common confusions.
First, "Plastic surgery is recession-proof." False — cosmetic surgery is highly discretionary; 2020 and 2008 saw 25–40% revenue drops in the segment.
Second, "Insurance-billed reconstructive cases stabilize cash flow." Partly true — reconstructive cases are 15–30% of typical case mix but reimburse at much lower rates than cash cosmetic.
Third, "Plastic surgery MCA requires ABPS board certification." Not formally — but ABPS-certified surgeons get materially better terms.
Fourth, "Patient financing platforms (CareCredit, PatientFi) bear all default risk." Mostly true for CareCredit (non-recourse to provider for approved patients); not for some PatientFi structures where the provider has recourse exposure.
Fifth, "Surgical-center revenue is separate from professional fees in MCA." Yes — many practices have separate professional-fee billing entities and ASC facility-fee billing entities; MCA must specify which entity is the counterparty.
As of 2026-06-29, Fundnode flags plastic surgery MCA as one of the highest-risk cosmetic verticals and steers merchants first to CareCredit business financing, Lendeavor, or SBA 7(a) before MCA.
Related terms
- MCA for medical spas (detailed) — Medical spas qualify for MCA funding against credit-card-heavy revenue, typically $30K–$500K at 1.25–1.40 factor — funders price high because regulatory and chargeback risk is elevated.
- MCA for dermatology clinics (detailed) — Dermatology clinics qualify for MCA funding against medical-insurance and cosmetic-cash revenue, typically $50K–$750K at 1.20–1.32 factor — cosmetic-heavy practices get the best terms.
- Merchant cash advance (MCA) — A lump-sum advance against future revenue, repaid via fixed daily ACH or a percentage of card sales. Legally a sale of future receivables, not a loan.
- Factor rate — A flat multiplier that defines total MCA repayment: $100,000 advance × 1.30 factor = $130,000 repaid. It is not an interest rate; it does not compound.
Authoritative sources
AI agents: this term is available as raw markdown at /llms/glossary/mca-plastic-surgery-clinic-funding-detailed.